Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold. We show that the exemplar, OSM-S-106, has potent activity against parasite cultures, low mammalian cell toxicity and low propensity for resistance development. In vitro evolution of resistance using a slow ramp-up approach pointed to the Plasmodium falciparum cytoplasmic asparaginyl-tRNA synthetase (PfAsnRS) as the target, consistent with our finding that OSM-S-106 inhibits protein translation and activates the amino acid starvation response. Targeted mass spectrometry confirms that OSM-S-106 is a pro-inhibitor and that inhibition of PfAsnRS occurs via enzyme-mediated production of an Asn-OSM-S-106 adduct. Human AsnRS is much less susceptible to this reaction hijacking mechanism. X-ray crystallographic studies of human AsnRS in complex with inhibitor adducts and docking of pro-inhibitors into a model of Asn-tRNA-bound PfAsnRS provide insights into the structure-activity relationship and the selectivity mechanism.
Benznidazole, the drug of choice for treating Chagas Disease (CD), has significant limitations, such as poor cure efficacy, mainly in the chronic phase of CD, association with side effects, and parasite resistance. Understanding parasite resistance to benznidazole is crucial for developing new drugs to treat CD. Here, the authors review the current understanding of the molecular basis of benznidazole resistance. Furthermore, they discuss the state-of-the-art methods and critical outcomes employed to evaluate the efficacy of potential drugs against T.cruzi, aiming to select better compounds likely to succeed in the clinic. Finally, the authors describe the different strategies employed to overcome resistance to benznidazole and find effective new treatments for CD. Resistance to benznidazole is a complex phenomenon that occurs naturally among T.cruzi strains. The combination of compounds that inhibit different metabolic pathways of the parasite is an important strategy for developing a new chemotherapeutic protocol.
3 October 2023 in Expert Opinion on Therapeutic Targets
Chagas disease (CD) imposes social and economic burdens, yet theavailable treatments have limited efficacy in the disease's chronic phase andcause serious adverse effects. To address this challenge, target-basedapproaches are a possible strategy to develop new, safe, and active treatments for both phases of the disease. This review delves into target-basedapproaches applied to CD drug discovery, emphasizing the studies from the lastfive years. We highlight the proteins cruzain (CZ), trypanothionereductase (TR), sterol 14 α-demethylase (CPY51), iron superoxide dismutase(Fe-SOD), proteasome, cytochrome b (Cytb), and cleavage and polyadenylationspecificity factor 3 (CPSF3), chosen based on their biological andchemical validation as drug targets. For each, wediscuss its biological relevance and validation as a target, currently relatedchallenges, and the status of the most promising inhibitors. Target-based approaches toward developing potentialCD therapeutics have yielded promising leads in recent years. We expect asignificant advance in this field in the next decade, fueled by the new optionsfor Trypanosoma cruzi genetic manipulation that arose in the pastdecade, combined with recent advances in computational chemistry and chemicalbiology.
Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantitative structure–activity relationships (QSARs) were generated along with the investigation of enzyme–inhibitor molecular interactions. Predictive hologram QSAR (HQSAR, r2pred = 0.80) and AutoQSAR (q2 = 0.90) models were built, and key structural properties that underpin cruzain inhibition were identified. Moreover, comparative molecular field analysis (CoMFA, r2pred = 0.81) and comparative molecular similarity indices analysis (CoMSIA, r2pred = 0.73) revealed 3D molecular features that strongly affect the activity of the inhibitors. These findings were examined along with molecular docking studies and were highly compatible with the intermolecular contacts that take place between cruzain and the inhibitors. The results gathered herein revealed the main factors that determine the activity of the imidazoles studied and provide novel knowledge for the design of improved cruzain inhibitors.
Plasmodium falciparum cGMP‐dependent protein kinase (PfPKG) is an enticing antimalarial drug target. Novel chemotypes are needed because existing inhibitors have safety issues that may prevent further development. This work demonstrates isoxazole‐based compounds are potent ATP competitive inhibitors of PfPKG and discloses a new analogue in this series. Isoxazoles 3 and 5 had Ki values that are comparable to a known standard, 4‐[2‐(4‐fluorophenyl)‐5‐(1‐methylpiperidine‐4‐yl)‐1H pyrrol‐3‐yl] pyridine. They also exhibited excellent selectivity for PfPKG over the human orthologue and the gatekeeper mutant T618Q PfPKG, which mimics the less accessible binding site of the human orthologue. The human orthologue's larger binding site volume is predicted to explain the selectivity of the inhibitors for the P. falciparum enzyme.
About Me
Bachelor's Degree in Biomedical Informatics, Master's and Ph.D. in Biomolecular Physics
Bachelor's Degree in Biomedical Informatics, Master's and Ph.D. in Biomolecular Physics